These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 20689464)

  • 1. Low-dose tibolone (1.25 mg/d) does not affect muscle strength in older women.
    Ribom EL; Svensson P; van Os S; Larsson M; Naessen T
    Menopause; 2011 Feb; 18(2):194-7. PubMed ID: 20689464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tibolone low dose (1.25 mg/d) therapy and postural balance in elderly women.
    Naessen T; Lindmark B; Larsen HC; van Os S; Larsson M
    Maturitas; 2009 Jan; 62(1):72-5. PubMed ID: 19097714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postmenopausal HRT and tibolone in relation to muscle strength and body composition.
    Jacobsen DE; Samson MM; Kezic S; Verhaar HJ
    Maturitas; 2007 Sep; 58(1):7-18. PubMed ID: 17576043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raloxifene and tibolone in elderly women: a randomized, double-blind, double-dummy, placebo-controlled trial.
    Jacobsen DE; Melis RJ; Verhaar HJ; Olde Rikkert MG
    J Am Med Dir Assoc; 2012 Feb; 13(2):189.e1-7. PubMed ID: 21741883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.
    Christodoulakos GE; Botsis DS; Lambrinoudaki IV; Papagianni VD; Panoulis CP; Creatsa MG; Alexandrou AP; Augoulea AD; Dendrinos SG; Creatsas GC
    Maturitas; 2006 Mar; 53(4):413-23. PubMed ID: 16140483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.
    Hammar ML; van de Weijer P; Franke HR; Pornel B; von Mauw EM; Nijland EA;
    BJOG; 2007 Dec; 114(12):1522-9. PubMed ID: 17995496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy.
    Perez-Medina T; Bajo-Arenas J; Haya J; Sanfrutos L; Iniesta S; Bueno B; Castelo-Branco C
    Menopause; 2003; 10(6):534-7. PubMed ID: 14627862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis.
    Eilertsen AL; Sandvik L; Mowinckel MC; Andersen TO; Qvigstad E; Sandset PM
    Thromb Res; 2007; 120(3):371-9. PubMed ID: 17156824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.
    Eilertsen AL; Liestøl S; Mowinckel MC; Hemker HC; Sandset PM
    Thromb Haemost; 2007 Jun; 97(6):938-43. PubMed ID: 17549295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Tibolone therapy in postmenopausal women with a history of many risk factors].
    Szántó F
    Orv Hetil; 2003 Apr; 144(15):701-4. PubMed ID: 12774429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of tibolone on ocular functions in postmenopausal women.
    Verit FF; Oguz H; Ozkul Y; Bozkurt O
    Arch Gynecol Obstet; 2007 Apr; 275(4):255-61. PubMed ID: 17047975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tibolone for prevention and treatment of postmenopausal osteoporosis.
    Ettinger B
    Maturitas; 2007 May; 57(1):35-8. PubMed ID: 17350774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive function variations in postmenopausal women treated with continuous, combined HRT or tibolone. A comparison.
    Pan HA; Wang ST; Pai MC; Chen CH; Wu MH; Huang KE
    J Reprod Med; 2003 May; 48(5):375-80. PubMed ID: 12815913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conjugated estrogen/progestagen versus tibolone hormone replacement therapy in postmenopausal women: Effects on carbohydrate metabolism and serum sex hormone-binding globulin.
    Odmark IS; Carlström K; Jonsson B; Jonasson AF
    Maturitas; 2006 Jan; 53(1):89-96. PubMed ID: 15964160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of hormone replacement therapy and tibolone on serum leptin levels in postmenopausal women.
    Lambrinoudaki IV; Christodoulakos GE; Panoulis CP; Rizos DA; Dendrinos SG; Liakakos T; Augoulea AD; Creatsas GC
    Maturitas; 2004 Jun; 48(2):107-13. PubMed ID: 15172084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method.
    Eilertsen AL; Karssemeijer N; Skaane P; Qvigstad E; Sandset PM
    BJOG; 2008 May; 115(6):773-9. PubMed ID: 18355366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.
    Kenemans P; Speroff L;
    Maturitas; 2005 May; 51(1):21-8. PubMed ID: 15883105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Reasons for abandonment of hormone replacement therapy with tibolone in menopausal women].
    Zayas-Jaime FJ; Ornelas-Aguirre JM; Pérez-Nápoles DE
    Ginecol Obstet Mex; 2013 Oct; 81(10):593-601. PubMed ID: 24483042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
    Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
    Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 7alpha-Methyl-ethinyl estradiol is not a metabolite of tibolone but a chemical stress artifact.
    Dröge MJ; Oostebring F; Oosting E; Verheul HA; Kloosterboer HJ
    Menopause; 2007; 14(3 Pt 1):474-80. PubMed ID: 17237734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.